BioMedNewsBreaks

FridayMar 11, 2022 1:25 pm

BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba

AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The…

Continue Reading

ThursdayMar 10, 2022 11:28 am

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company operates, as a supplier for the Special Access Program (“SAP”). “SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding…

Continue Reading

WednesdayMar 09, 2022 12:40 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both…

Continue Reading

TuesdayMar 08, 2022 1:28 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will host a fireside chat with Scoth Henry, managing director and head of pharmaceuticals research at Roth Capital Partners, on Tuesday, March 15. In addition to the live fireside chat, InMed’s virtual Roth Conference presentation is now available on-demand by visiting https://ibn.fm/fsWdF. A webcast will be made available to investors following the event in the investor relations section of…

Continue Reading

TuesdayMar 08, 2022 12:23 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Approval from Health Canada Recognizing RYAH Smart Medical Inhaler System as Medical Device

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a Health Canada Medical Device License (“MDL”) for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). According to the update, Health Canada License number 107475 allows RYAH to market its Smart Medical Inhaler System to medical patients in Canada and potentially represents a significant boost to RYAH’s growth strategy. “The approval from Health Canada recognizing the RYAH Smart Inhaler System as a medical device is a major step towards…

Continue Reading

FridayMar 04, 2022 12:14 pm

BioMedNewsBreaks – Why AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Is ‘One to Watch’

AREV Life Sciences (CSE: AREV) (OTC: AREVF) is dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful industry collaborations. Its leadership team is focused on driving discovery programs for clinical complexities demonstrated by malnutrition, the inflammatory response system and viral infectious diseases. “AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (‘SAB’), experienced staff, and executive leadership to drive its product pipeline,” reads a recent article discussing the company. “AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine…

Continue Reading

ThursdayMar 03, 2022 2:59 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market

InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded its portfolio and its presence in the growing rare cannabinoid market,” reports a recent article. “CBT is the first of several new products InMed is planning to launch in the first half of 2022 in…

Continue Reading

ThursdayMar 03, 2022 12:37 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Operationally 2021 was a terrific year for the company as we established the global framework for building and expanding our potentially pivotal clinical study of Berubicin for the treatment of GBM. Our priority remains focused…

Continue Reading

ThursdayMar 03, 2022 11:13 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. Members of Mydecine’s management team will be available for one-on-one or small group meetings, which may be scheduled by emailing contact@mydecineinc.com. Investor meetings will focus on the company’s research and development pipeline, patent strategies, as well as clinical trials involving targeted drug candidates and therapeutic…

Continue Reading

TuesdayMar 01, 2022 12:26 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing…

Continue Reading